![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.471, 2005-01, pp. : 7-7
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Eletriptan efficacy for migraine not influenced by previous triptan use
Inpharma, Vol. 1, Iss. 1584, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Triptan properties related to migraine recurrence
Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Triptan use in France not currently ideal
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 452, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Triptan use in France not currently ideal
Inpharma, Vol. 1, Iss. 1437, 2004-01 ,pp. :